Cyclerion Therapeutics, Inc. (CYCN)

3.1200 +0.0200 (+0.65%) At close: 4:00PM EDT

Cyclerion Therapeutics, Inc.

301 Binney Street
Cambridge, MA 02142
United States
857 327 8778
http://www.cyclerion.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 34

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Peter M. Hecht	CEO & Director	110.78k	N/A	1964
Dr. Andreas Busch Ph.D.	Chief Scientific Officer	662.42k	N/A	1963
Ms. Anjeza Gjino	CFO & Corp. Sec.	N/A	N/A	1983
Ms. Cheryl Gault	Chief Operating Officer	N/A	N/A	1979
Dr. Todd Milne Ph.D.	VP of Corp. Devel.	N/A	N/A	N/A
Ms. Jessica Rennekamp	Associate Director of Corp. Communications	N/A	N/A	N/A
Mr. Christopher Winrow	Sr. Director of Clinical Devel. & Neuroscience Program Lead	N/A	N/A	N/A
Ms. Jennifer Chickering	Sr. Director of Clinical Strategy	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Cyclerion Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2021 is 3. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.